Biomarkers for Hematologic Malignacies
AssigneeGeorgia Health Sciences University Research Institute, Inc.
InventorsJin-Xiong She, Bo Chen
Life of this patent
Estimating the term…
Abstract
It has been discovered that STAT5 phosphorylation and CD150 are effective biomarkers for detecting, diagnosing, and monitoring hematological malignancies, including for example lymphomas. Compositions and methods for identifying therapeutic agents for the treatment of hematologic malignancies using p-STAT5, CD150 or both as biomarkers are described.
Claims25
A method for treating a subject having or suspected of having a hematological malignancy comprising
- administering to the subject an effective amount of an anticancer agent to reduce expression of CD150 on CD8+ cells by an amount effective to treat one or more symptoms of the hematological malignancy.
A method for determining the efficacy of a treatment for a hematological malignancy on a subject having a hematological malignancy comprising
- determining the presence of p-STAT5, CD150, or both, in or on immune cells in a sample from the subject undergoing the treatment,
- wherein an increased presence of p-STAT, CD150 or both in or on the immune cells in the sample from the subject relative to a control is indicative that the treatment for the hematological malignancy is ineffective for the subject.
A transgenic mammal overexpressing a constitutively active form of STAT5.
A method for identifying therapeutic agents for the treatment of hematological malignancies comprising:
- administering a test compound to a transgenic animal overexpressing a constitutively active form of STAT5;
- determining the presence or absence of hematological malignancies or symptoms thereof in the transgenic animal after administration of the test compound,
- wherein a reduced amount of hematological malignancies, symptoms, or biomarkers thereof in the transgenic animal after treatment with the test compound is indicative that the test compound is a therapeutic agent for the treatment of the hematological malignancies.
A method of detecting or diagnosing hematologic malignancies or the risk of developing hematologic malignancies in a subject comprising
- determining the presence of p-STAT5, CD150, or both in immune cells in a sample from the subject
- wherein an increased presence of p-STAT, CD150 or both in the immune cells in the sample from the subject is indicative of a hematological malignancy or is indicative of an increased risk of the subject developing a hematological malignancy relative to a control.
A method for treating a subject having or suspected of having a hematological malignancy comprising
- administering to the subject an effective amount of an inhibitor of the STAT5 pathway to inhibit or reduce expression of CD150 on immune cells.
Dependencies are inferred from the claim text.